High-sensitivity C-reactive protein, vascular imaging, and vulnerable plaque : More evidence to support trials of antiinflammatory therapy for cardiovascular risk reduction

Circulation: Cardiovascular Imaging

Volumn 4, Issue 3, 2011, Pages 195-197

  Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

C reactive protein; Cardiovascular diseases; Editorials; Imaging; Inflammation; Plaque

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CANAKINUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; ROSUVASTATIN; BIOLOGICAL MARKER;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; EDITORIAL; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; NOTE; RADIOGRAPHY; RISK ASSESSMENT; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HUMANS; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051742592     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.111.965053     Document Type: Editorial

References (33)

1. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet. 2010;375:132-140.
2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
3. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25:567-579.
4. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: Executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance J Am Coll Cardiol. 2010;56:2182-2199.
5. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA. 2007;97:611-619.
6. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds Risk Score for Men. Circulation. 2008;118: 2243-2251.
7. Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011;57:784-791.
8. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17:2167-2176. (Pubitemid 28057118)
9. Folsom AR, Pankow JS, Tracy RP, Arnett DK, Peacock JM, Hong Y, Djousse L, Eckfeldt JH. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001;88:112-117. (Pubitemid 32607694)
10. Hunt ME, O'Malley PG, Vernalis MN, Feuerstein IM, Taylor AJ. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J. 2001;141:206-210. (Pubitemid 32128724)
11. Redberg RF, Rifai N, Gee L, Ridker PM. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: Implications for coronary artery disease screening. J Am Coll Cardiol. 2000;36:39-43. (Pubitemid 30466109)
12. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, Pestaner J, Smialek J, Virmani R. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies. Circulation. 2002;105:2019-2023. (Pubitemid 34465262)
13. Zieske AW, Tracy RP, McMahan CA, Herderick EE, Homma S, Malcom GT, McGill HC Jr, Strong JP. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 2005;25:1237-1243. (Pubitemid 40776615)
14. Jarvisalo MJ, Harmoinen A, Hakanen M, Paakkunainen U, Viikari J, Hartiala J, Lehtimaki T, Simell O, Raitakari OT. Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol. 2002;22:1323-1328. (Pubitemid 34875744)
15. Rubin J, Chang H-J, Nasir K, Blumenthal RS, Blaha MJ, Choi E-K, Chang S-A, Yoon YE, Chun E-J, Choi S-I, Agatston AS, Rivera JJ. Association between high-sensitivity C-reactive protein and coronary plaque subtypes assessed by 64-slice coronary CT angiography in an asymptomatic population. Circ Cardiovasc Imaging. 2011;4:201-209.
16. Hoffmann U, Moselewski F, Nieman K, Jang IK, Ferencik M, Rahman AM, Cury RC, Abbara S, Joneidi-Jafari H, Achenbach S, Brady TJ. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol. 2006; 47:1655-1662.
17. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, Naruse H, Ishii J, Hishida H, Wong ND, Virmani R, Kondo T, Ozaki Y, Narula J. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49-57.
18. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, Nakamura Y, Yamashita H, Yamagishi H, Takeuchi K, Naruko T, Haze K, Becker AE, Yoshikawa J, Ueda M. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: An intravascular ultrasound study. Circulation. 2004;110:3424-3429. (Pubitemid 39602220)
19. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol. 2001;21:1618-1622. (Pubitemid 34215581)
20. Hausleiter J, Meyer T, Hadamitzky M, Kastrati A, Martinoff S, Schomig A. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol. 2006;48:312-318.
21. Bonow RO. Clinical practice. Should coronary calcium screening be used in cardiovascular prevention strategies? N Engl J Med. 2009;361: 990-997.
22. O'Malley PG. The proof of atherosclerosis imaging is in the evidence: Where are the studies? Arch Intern Med. 2011. [Epub ahead of print].
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: 1615-1622. (Pubitemid 28248586)
25. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-844. (Pubitemid 28397432)
26. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28. (Pubitemid 40075677)
27. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281-288. (Pubitemid 44297094)
28. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38. (Pubitemid 40075678)
29. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373: 1175-1182.
30. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. In press.
31. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361.
32. Rajama K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, Eklund KK. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS ONE. 2010;5:e11765.
33. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: Scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7(suppl 1):332-339.